Lacutoclax
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Lacutoclax
- Molecular weight
- 923.54
- Structure (SMILES)
- C[C@@H]1CN(c2cc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC(C)(C)CC4)CC3)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)c2cc3cc[nH]c3nc2O1
- lacutoclax
- Lacutoclax
- lacutoclax [INN]
- lacutoclax inn
- lacutoclax rocbrutinib
- lp 108
- CAS registry numbers
- 2291166-56-6
- ChEMBL ID
- CHEMBL5314523
- InChIKey
- CCDRQWAEZGRMTP-WJOKGBTCSA-N
- PubChem compound IDs
- 153515493
- FDA ingredient codes (UNII)
- PMG5245L91
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -toclax
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Hydrogen bond acceptors
- 12
- Hydrogen bond donors
- 3
- Polar surface area
- 175.27
- Calculated partition coefficient (ALogP)
- 8.79
- Calculated partition coefficient (XLogP)
- 8.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 12
- Heavy atoms
- 65
- Molecular formula
- C48H55ClN8O7S
- Monoisotopic mass
- 922.3602950
- Natural product
- No
- Recorded assays
- 4
- Active assays
- 4
Active assay types
- Confirmatory
Related records
Trials (5)
- A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
- A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
- A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
- Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
In development for (1)
- Neoplasm Phase 2